|
Castillo-Guardiola V, Sarabia-Meseguer MD, Marín-Vera M, Sánchez-Bermúdez AI, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. New insights into the performance of multigene panel testing: Two novel nonsense variants in BRIP1 and TP53 in a young woman with breast cancer. Cancer Genet. 2018 Dec;228-229:1-4. doi: 10.1016/j.cancergen.2018.06.002. Epub 2018 Jun 23. PubMed PMID: 30553462.
AÑO: 2018; IF: 2.183
|
|
Gabaldó Barrios X, Sarabia Meseguer MD, Marín Vera M, Sánchez Bermúdez AI, Macías Cerrolaza JA, Sánchez Henarejos P, Zafra Poves M, García Hernández MR, Cuevas Tortosa E, Aliaga Baño Á, Castillo Guardiola V, Martínez Hernández P, Tovar Zapata I, Martínez Barba E, Ayala de la Peña F, Alonso Romero JL, Noguera Velasco JA, Ruiz Espejo F. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers. Fam Cancer. 2017 Oct;16(4):477-489. doi: 10.1007/s10689-017-9985-x. PubMed PMID: 28477318.
AÑO: 2017; IF: 1.943
|
|
García-Vizcaíno EM, Liarte S, Alonso-Romero JL, Nicolás FJ. Sirt1 interaction with active Smad2 modulates transforming growth factor-β regulated transcription. Cell Commun Signal. 2017 Nov 29;15(1):50. doi: 10.1186/s12964-017-0205-y. PubMed PMID: 29187201; PubMed Central PMCID: PMC5706420.
AÑO: 2017; IF: 5.324
|
|
Fernández de Palencia Espinosa MÁ, Díaz Carrasco MS, Alonso Romero JL, de la Rubia Nieto A, Espuny Miró A. Potential drug-drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factors. Int J Clin Pharm. 2015 Dec;37(6):1021-7. doi: 10.1007/s11096-015-0195-z. Epub 2015 Sep 21. PubMed PMID: 26391788.
AÑO: 2015; IF: 2.305
|
|
Carballo-Santana, M; Martinez-Garcia, J; Sanchez-Henarejos, P; Ros, S; Marin, M; Marin, G; Garcia-Hernandez, MR; Soto, A; Balsalobre, J; Barcelo, A; Puertes, A; Turrez, E; Jimenez-Lucas, MD; Guirao, M; Cuellar, MA; Cano, A; Martinez-Lacaci, I; Alonso-Romero, JL. Reversal of azd6244 (selumetinib) resistance in primary cultures of colorectal cancer, by p70s6 kinase inhibition using bez-235. EUROPEAN JOURNAL OF CANCER. 2015; 51:S96-S97. 10.1016/S0959-8049(16)30289-1
AÑO: 2015; IF: 7.275
|